OncoCyte Corp (OCX)

OncoCyte Stock Analysis & Ratings

OCX Stock Chart & Stats

Day’s Range$1.12 - $1.15
52-Week Range$1.09 - $6.25
Previous Close$1.14
Average Volume (3M)489.92K
Market Cap$132.73M
P/E Ratio-1.6
Next EarningsAug 17, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)-0.70



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was OncoCyte’s price range in the past 12 months?
OncoCyte lowest stock price was $1.09 and its highest was $6.25 in the past 12 months.
    What is OncoCyte’s market cap?
    OncoCyte’s market cap is $132.73M.
      What is OncoCyte’s price target?
      The average price target for OncoCyte is $3.41. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $6.00 ,the lowest forecast is $1.40. The average price target represents 204.46% Increase from the current price of $1.12.
        What do analysts say about OncoCyte?
        OncoCyte’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
          When is OncoCyte’s upcoming earnings report date?
          OncoCyte’s upcoming earnings report date is Aug 17, 2022 which is in 89 days.
            How were OncoCyte’s earnings last quarter?
            OncoCyte released its earnings results on May 11, 2022. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.121 by $0.011.
              Is OncoCyte overvalued?
              According to Wall Street analysts OncoCyte’s price is currently Undervalued.
                Does OncoCyte pay dividends?
                OncoCyte does not currently pay dividends.
                What is OncoCyte’s EPS estimate?
                OncoCyte’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does OncoCyte have?
                OncoCyte has 118,510,000 shares outstanding.
                  What happened to OncoCyte’s price movement after its last earnings report?
                  OncoCyte reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.121. Following the earnings report the stock price went down -3.54%.
                    Which hedge fund is a major shareholder of OncoCyte?
                    Among the largest hedge funds holding OncoCyte’s share is Ardsley Advisory Partners. It holds OncoCyte’s shares valued at N/A.


                      OncoCyte Stock Analysis

                      The OncoCyte stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      OncoCyte Corp

                      OncoCyte Corp. is a pharmaceutical company. It is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company was founded in September 2009 and is headquartered in Alameda, CA.

                      Similar Stocks
                      Price & Change
                      Aspira Women's Health
                      Myriad Genetics
                      Exact Sciences

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis